Maxigen Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Maxigen Biotech has a total shareholder equity of NT$1.3B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.5B and NT$198.4M respectively. Maxigen Biotech's EBIT is NT$149.1M making its interest coverage ratio -5.3. It has cash and short-term investments of NT$543.8M.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | -5.3x |
| Cash | NT$543.76m |
| Equity | NT$1.33b |
| Total liabilities | NT$198.36m |
| Total assets | NT$1.53b |
Recent financial health updates
No updates
Recent updates
Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 20
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality
Mar 28Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?
Apr 22We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings
Apr 01Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Mar 16The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More
Feb 23Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?
Feb 02Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield
Jan 10Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?
Dec 14If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%
Nov 22
Financial Position Analysis
Short Term Liabilities: 1783's short term assets (NT$744.2M) exceed its short term liabilities (NT$196.6M).
Long Term Liabilities: 1783's short term assets (NT$744.2M) exceed its long term liabilities (NT$1.7M).
Debt to Equity History and Analysis
Debt Level: 1783 is debt free.
Reducing Debt: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 25.4%.
Debt Coverage: 1783 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1783 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 22:28 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maxigen Biotech Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Regina Lee | Capital Securities Corporation |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hsiu Chi Lin | Masterlink Securities Corp. |